The therapeutic effect of human adult stem cells derived from adipose tissue in endotoxemic rat model

International Journal of Medical Sciences

Volumn 10, Issue 1, 2012, Pages 8-18

  Shin, Soyoung ^a   Kim, Yonggoo ^a   Jeong, Sikyoung ^a   Hong, Sungyoup ^a   Kim, Insoo ^a   Lee, Woonjeong ^a   Choi, Seungphil ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Adipose tissue derived mesenchymal stem cells(ATSCs); Endotoxemia

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ADIPOSE TISSUE; ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELL; ADULT STEM CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTOXEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; KIDNEY PARENCHYMA; LUNG PARENCHYMA; MALE; MESENCHYMAL STEM CELL; MULTIPLE ORGAN FAILURE; NONHUMAN; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SEPSIS; SYSTEMIC DISEASE; THERAPY EFFECT;

ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS(ATSCS); ENDOTOXEMIA;

ADIPOSE TISSUE; ADULT STEM CELLS; ANIMALS; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MESENCHYMAL STEM CELL TRANSPLANTATION; RATS; TISSUE THERAPY;

EID: 84871355986     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.5385     Document Type: Article

References (43)

1. Lolis E, Bucala R. Therapeutic approaches to innate immunity: severe sepsis and septic shock. Nat Rev Drug Discov. 2003;177(3):635-74.
2. Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine/ inhibitor profiles reshape the understanding of the sirs/cars continuum in sepsis and predict mortality. J Immunol. 2006;177(3):1967-74.
3. Monneret G, Venet F, Pachot A, Lepape A. Monitoring Immune Dysfunctions in the Septic Patient: A New Skin for the Old Ceremony. Molmed. 2008;14(1-2):64-78.
4. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal Bacteraemia. Nature. 1987;330(6149):662-4.
5. Deans KJ, Haley M, Natanson C, Eichacker PQ, Minneci PC. Novel therapies for sepsis: a review. J Trauma. 2005;58(4):867-74.
6. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(5):1815-22.
7. Aggarwal S, Fibbe WD. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499-506.
8. Xu J, Woods CR, Mora AL, Joodi R, Brigham KL, Iyer S, et AL. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physio. 2007; 293(1):131-41.
9. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am j Respri Crit Care Med. 2010;182(8):1047-57.
10. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-7.
11. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211-28.
12. Chamberlain G, Fox J, Ashton B, Middleton J. Mesenchymal stem cells: their phenotype, differentiation capacity, immunological features and potential for homing. Stem Cells. 2007; 25(11):2739-49.
13. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfect. Nat Med. 1999;5(3):309-13.
14. Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med. 2004;8(3):301-16.
15. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 2004;36(4):568-84.
16. Dominici M, Hofmann TJ, Horwitz EM. Bone marrow mesenchymal cells: biological properties and clinical applications. J Biol Regul Homeost Agents. 2001;15(1):28-37.
17. Koc ON, Lazarus HM. Mesenchymal stem cells: heading into the clinic. Bone Marrow Transplant. 2001;27(3):235-9.
18. Dicker A, Le Blanc K, Aström G, van Harmelen V, gotherström C, BlomqviSt L, et al. Functional studies of mesenchymal stem cells derived from adult human adipose tissue. Exp Cell Res. 2005;308(2):28-90.
19. Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006;24(11):2582-91.
20. Imanaka H, Shimaoka M, Matsuura N, Nishimura M, Ohta N, Kiyono H. Ventilator-induced lung injury is associated with neutrophil infiltration, macrophage activation, and TGF-beta 1 mRNA upregulation in rat lungs. Anesth Analg. 2001;92(2):428-36.
21. Rigol M, Solanes N, Farre J, Roura S, Roque M, Berruezo A, et al. Effects of Adipose Tissue-Derived Stem Cell Therapy After Myocardial Infarction: Impact of the Route of Administration. J Card Failure. 2010;16(4):357-66.
22. Wheeler AP. Recent developments in the diagnosis and management of severe sepsis. Chest. 2007;132(6):1967-76.
23. Mansilla E, Marin G, Sturla F, Drago HE, Gil MA, Salas E, et al. Human mesenchymal stem cells are tolerized by mice and improve skin and spinal cord injuries. Transplant Proceed. 2005;37(1):292-4.
24. Shirley HJ, Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, et al. Prevention of LPS-Induced Acute Lung Injury in Mice by Mesenchymal Stem Cells Overexpressing angiopoietin1. PLos Med. 2007;4(9):e269.
25. McCulloch EA, Till JE. Perspectives on the properties of stem cells. Nat Med. 2005;11(10):1026-8.
26. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol. 2007;179(3):1855-63.
27. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363(9419):1439-41.
28. Gnecchi M, He H, Melo LG, Noiseaux N, Morello F, de Boer RA, et al. Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells. 2009;27(4):971-9.
29. Lange C, Togel F, Ittrich H, Clayton F, Nolte-Ernsting C, Zander AR, et al. Administered mesenchymal stem cells enhance recovery from ischemia /reperfusion induced acute renal failure in rats. Kidney Int. 2005;68(4):1613-7.
30. Estrada EJ, Valacchi F, Nicora E, Brieva S, Esteve C, Froud T, et al. Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplant. 2008;17(12):1295-304.
31. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Boanni I, Gerdoni E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106(5):1755-61.
32. Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pacsual I, Peiro C, Rodriguez- Montes JA, et al. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48(7):1416-23.
33. Gonzalez MA, Gonzalez-Rey E, Rico L, Busher D, Delgado M. Adipose- derived mesenchymal Stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009;136(3):978-89.
34. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelle A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15(1):42-9.
35. Krampera M, Sartoris S, Liotta F, Pasini A, Angeli R, Cosmi L, et al. Immune regulation by mesenchymal stem cells derived from adult spleen and thymus. Stem Cells Dev. 2007;16(5):797-810.
36. Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Hematol. 2005;129(1):118-29.
37. Gonzalez-Rey E, Anderson P, González MA, Rico L, Büscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58(7):929-39.
38. M Gnecchi, Z Zhang, A Ni, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2009;103(11):1204-19.
39. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA. 2009;106(38):16357-62.
40. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149(2):353-63.
41. Rocco PR, Pelosi P. Pulmonary and extrapulmonary acute respiratory distress syndrome: myth or reality? Curr Opin Crit Care. 2008;14(1):50-5.
42. Doi K, Leelahavanichkul A, Yuen PS, Star RA. Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest. 2009;119(10):2868-78.
43. Weil BR, Manukyan MC, Herrmann JL, Wang Y, Abarbanell AM, Poynter JA, et al. Mesenchymal stem cells attenuate myocardial functional depression and reduce systemic and myocardial inflammation during endotoxemia. Surgery. 2010;148(2):444-52.